RIV Capital, Cansortium announce NY Cannabis Control Board approval of merger
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 10 2024
0mins
Should l Buy ?
Business Combination Approval: RIV Capital and Cansortium have received approval from the New York Cannabis Control Board for their business combination, expected to close in Q4 2024, pending other conditions.
Market Expansion Plans: The integration aims to enhance competitiveness and resource availability to meet the growing demand for cannabis products in New York, leveraging Fluent's expertise in both adult-use and medical cannabis markets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
